Germany’s Aging Population and the Pruritus Therapeutics Market in Europe Explained
Chronic itch is more than an annoyance. It disrupts sleep, affects mental well-being, and often signals a larger condition such as atopic dermatitis, kidney disease, or liver disorders. That burden is why pruritus therapeutics is an area of active investment in dermatology and immunology. Here is a look at where the market stands, what is driving it, and how it differs by region.
Market Size & Growth Forecasts
According to Grand View Research, the global pruritus therapeutics market was valued at USD 9.3 billion in 2025. It is estimated at USD 9.7 billion in 2026 and is projected to reach USD 13.4 billion by 2033, a CAGR of 4.8% from 2026 to 2033.
Some segments are growing faster than the market as a whole:
- By disease: Atopic dermatitis led in 2025 with a 50.8% revenue share. Allergic contact dermatitis is expected to grow fastest, at a 4.8% CAGR, as allergies, skin sensitivities, and urban pollution increase.
- By product: Antihistamines held a 61.4% share in 2025. They are widely used as a first-line option for itch and allergic skin conditions.
- By distribution channel: Retail pharmacies led with 58.8%, but online pharmacies are projected to grow fastest at a 5.9% CAGR, helped by home delivery, competitive pricing, and the shift to digital healthcare.
Go Deeper! Have a specific question about the market? Ask Prism AI about the Global Pruritus Therapeutics Market. Get instant answers to questions related to market sizing, growth drivers and their impact, and more.
Growth Drivers & Competitive Landscape
What is driving demand
The main driver is the rising prevalence of chronic pruritus linked to atopic dermatitis, prurigo nodularis, chronic kidney disease, and cholestatic liver disease. Several factors reinforce this:
- Targeted therapies are expanding treatment options. Patients who do not respond to conventional treatments now have more choices. In February 2025, for example, the European Commission approved Galderma’s Nemluvio (nemolizumab) for moderate-to-severe atopic dermatitis and prurigo nodularis.
- Awareness is improving. Updated treatment guidelines and greater physician awareness support earlier diagnosis and wider use of advanced therapies.
- Populations are aging. Itch becomes more common with age, which increases long-term demand.
- OTC topicals are popular. Patients often choose them for low cost and easy availability, which encourages manufacturers to invest in OTC products.
What is holding the market back
Cost is the biggest barrier. Biologics and targeted therapies are expensive, reimbursement policies vary by country, and many patients must try several standard treatments before qualifying for advanced options. Delayed diagnosis and limited access to dermatologists add to the problem, especially in low- and middle-income countries.
Where the opportunity is
Many forms of itch tied to liver disease, kidney disease, and neurological disorders still have few approved treatments. Companies are expanding into these indications. In March 2026, GSK licensed linerixibat, an investigational therapy for cholestatic pruritus in primary biliary cholangitis, to Alfasigma.
Who is competing
The market is led by established immunology and dermatology players such as AbbVie, Amgen, Astellas Pharma, Bristol-Myers Squibb, GSK, Novartis, Pfizer, and Sanofi. They compete through label expansions, partnerships, and investment in targeted therapies. Their strengths are broad portfolios, global regulatory experience, and strong ties with dermatologists and hospitals. Their challenges are high R&D costs, long development timelines, and pricing and reimbursement pressure.
Cara Therapeutics and Teva are among the emerging players, focusing on niche indications and differentiated mechanisms. Their limited commercial reach and reliance on clinical and regulatory success are the main constraints.
Want the full data behind these numbers? Download the free sample report for market estimates, trend analysis, and forecast data.
Regional Market Dynamics
North America: the leader
North America held the largest share, 38.6%, of the global market in 2025, with the U.S. as its biggest contributor. Strong healthcare infrastructure, high spending, a high prevalence of dermatological conditions, and active R&D from companies such as AbbVie, Amgen, and Pfizer support demand. New product launches and favorable government initiatives add to this.
Europe: a mature, research-driven market
Growth in Europe is supported by the rising prevalence of atopic dermatitis and psoriasis, and by drugmakers investing in R&D and pipelines. Germany stands out for its aging population, with roughly 22% of residents aged 65 or older, and for its robust healthcare system and awareness campaigns.
Asia Pacific: the fastest-growing region
Asia Pacific is projected to grow fastest, at a 6.1% CAGR. Contributing factors include research into how skin conditions present differently across Asian populations, supportive government initiatives in Japan and Australia, and clinical progress such as Kyowa Kirin’s positive Phase 3 results for rocatinlimab in atopic dermatitis in Japan. India is expected to be the fastest-growing country in the region, driven by its large population, rising eczema and psoriasis prevalence, and growing awareness. In January 2024, Pfizer and Glenmark partnered to launch abrocitinib in India, the first oral advanced systemic treatment there for moderate-to-severe atopic dermatitis.
Plan your U.S. market strategy
Understanding where care is delivered is as important as understanding demand. Explore the U.S. Healthcare Facility Mapping & Intelligence Platform to map and analyze healthcare facilities across the country.
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Jogos
- Gardening
- Health
- Início
- Literature
- Music
- Networking
- Outro
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness